FRANKLIN LAKES, N.J.,
July 21, 2020 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, today announced additional pandemic
orders for needles and syringes from the
United States and Canada
totaling 177 million injection devices.
The new U.S. order for 140 million injection devices brings
total U.S. orders from BD to 190 million devices. The new Canadian
order for 37 million brings total Canadian orders from BD to 75
million devices. Across the world, BD has received total orders of
330 million needles and syringes from the U.S., Canada and the United Kingdom. A majority of these orders
will be delivered by the end of December
2020 in anticipation of a vaccine being approved late this
year or early 2021. BD continues to be in discussions with
governments around the world on the need to place orders
immediately for early 2021 delivery.
Importantly, based on BD's manufacturing capability, the company
does not expect these orders will impact BD's ability to fulfill
existing customer requirements for needles and syringes, including
the annual flu vaccination and childhood immunization
campaigns.
"Proactive actions taken by the U.S., Canada and the U.K. to order injection devices
now will help these countries be ready to administer a vaccine when
one is approved and ready," said Rick
Byrd, president of Medication Delivery Solutions for BD.
"BD's commitment to manufacture hundreds of millions of needles and
syringes for the global COVID-19 response reinforces the company's
dedication to helping the health care community control and defeat
this virus."
In addition, on July 8, BD
announced a $70 million investment to
expand needle and syringe production at its facilities in
Nebraska as part of a strategic,
public-private partnership with the Biomedical Advanced Research
and Development Authority (BARDA), part of Office of the Assistant
Secretary for Preparedness and Response at the U.S. Health and
Human Services, and the Department of Defense's Joint Program
Executive Office for Chemical, Biological, Radiological and Nuclear
Defense (JPEO-CBRND), to develop new manufacturing lines
for injection devices that will provide priority access to
the U.S. government for hundreds of millions of syringes and
needles to support current and future pandemic vaccination
efforts.
As part of the partnership, BARDA collaborated with JPEO-CBRND
to invest an estimated $42 million
into a $70 million capital project to
further expand BD's operations and manufacturing capacity in
Nebraska, where the company has
manufactured medical devices for nearly 70 years. The new capacity
is expected to be online within 12 months and once completed, the
federal government will have priority access to injection devices
from these new manufacturing lines to support vaccination efforts
for COVID-19 and future pandemics. Learn more about how BD is
preparing for global COVID-19 vaccination preparations on the BD
blog.
BD is the largest manufacturer of injection devices in the
world, producing billions of syringes and needles annually through
its global manufacturing network. In addition to ramping up
manufacturing of needles and syringes, BD has been working closely
with the White House Coronavirus Task Force, the U.S. Department of
Health and Human Services (HHS) and other federal agencies to
expand access to diagnostic testing and support treatment of
COVID-19 patients. Through June, the company has supplied health
care providers globally with approximately 48 million swabs for flu
and COVID-19 testing, more than 2.85 million COVID-19 rapid
molecular diagnostic tests on the BD MAX™ System and millions of
products used in the treatment of COVID-19 patients, including
infusion pumps, infusion sets and catheters. BD Biosciences
instruments are also being used by researchers around the world to
better understand the human immune response to COVID-19.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its 65,000
employees have a passion and commitment to help enhance the safety
and efficiency of clinicians' care delivery process, enable
laboratory scientists to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. By working in
close collaboration with customers, BD can help enhance outcomes,
lower costs, increase efficiencies, improve safety and expand
access to health care. For more information on BD, please visit
bd.com.
Forward-Looking Statements
This press
release contains certain forward-looking statements regarding BD's
manufacturing operations. Forward-looking statements involve risks
and uncertainties that could cause actual results to differ
materially from those expressed or implied in such statements, many
of which are beyond the company's control. BD expressly disclaims
any undertaking to update any such statements set forth herein to
reflect events or circumstances after the date hereof, except as
required by applicable laws or regulations.
Contacts:
|
|
Troy
Kirkpatrick
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
858.617.2361
|
201.847.5378
|
troy.kirkpatrick@bd.com
|
Monique_Dolecki@bd.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bd-receives-additional-orders-for-177-million-injection-devices-for-us-canada-covid-19-vaccine-preparations-301096584.html
SOURCE BD (Becton, Dickinson and Company)